Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 13275.0%.

  • Northwest Biotherapeutics' EBITDA Margin fell 71800400.0% to 13275.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 9862.54%, marking a year-over-year decrease of 52633500.0%. This contributed to the annual value of 6055.35% for FY2024, which is 26401400.0% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its EBITDA Margin stood at 13275.0% for Q3 2025, which was down 71800400.0% from 14645.8% recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' EBITDA Margin ranged from a high of 1473.18% in Q1 2023 and a low of 14645.8% during Q2 2025
  • In the last 5 years, Northwest Biotherapeutics' EBITDA Margin had a median value of 5045.24% in 2022 and averaged 5992.91%.
  • Per our database at Business Quant, Northwest Biotherapeutics' EBITDA Margin soared by 2000000000bps in 2021 and then crashed by -110701200bps in 2025.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' EBITDA Margin stood at 2871.14% in 2021, then dropped by -6bps to 3044.89% in 2022, then fell by -12bps to 3402.7% in 2023, then crashed by -223bps to 11006.06% in 2024, then decreased by -21bps to 13275.0% in 2025.
  • Its EBITDA Margin was 13275.0% in Q3 2025, compared to 14645.8% in Q2 2025 and 5667.2% in Q1 2025.